JP2020531002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531002A5 JP2020531002A5 JP2020507675A JP2020507675A JP2020531002A5 JP 2020531002 A5 JP2020531002 A5 JP 2020531002A5 JP 2020507675 A JP2020507675 A JP 2020507675A JP 2020507675 A JP2020507675 A JP 2020507675A JP 2020531002 A5 JP2020531002 A5 JP 2020531002A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- amino acid
- igg
- acid substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 120
- 108090000765 processed proteins & peptides Proteins 0.000 claims 120
- 102000004196 processed proteins & peptides Human genes 0.000 claims 120
- 150000001413 amino acids Chemical group 0.000 claims 76
- 235000001014 amino acid Nutrition 0.000 claims 68
- 238000006467 substitution reaction Methods 0.000 claims 62
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 18
- 235000018102 proteins Nutrition 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 235000004279 alanine Nutrition 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 11
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 11
- 239000004473 Threonine Substances 0.000 claims 11
- 241000283073 Equus caballus Species 0.000 claims 9
- 241001465754 Metazoa Species 0.000 claims 9
- 239000000833 heterodimer Substances 0.000 claims 9
- 241000282326 Felis catus Species 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 8
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 8
- 241000282465 Canis Species 0.000 claims 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 7
- 239000004471 Glycine Substances 0.000 claims 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 6
- 229940024606 amino acid Drugs 0.000 claims 6
- 235000018417 cysteine Nutrition 0.000 claims 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 5
- 239000004475 Arginine Substances 0.000 claims 4
- 241000282324 Felis Species 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 4
- 238000007913 intrathecal administration Methods 0.000 claims 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 241000282472 Canis lupus familiaris Species 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241000282327 Felis silvestris Species 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 238000012575 bio-layer interferometry Methods 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 239000004474 valine Chemical group 0.000 claims 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 102000051325 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000007919 intrasynovial administration Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545858P | 2017-08-15 | 2017-08-15 | |
| US62/545,858 | 2017-08-15 | ||
| PCT/IB2018/056142 WO2019035010A1 (en) | 2017-08-15 | 2018-08-15 | IGG VARIANTS FOR VETERINARY USE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020531002A JP2020531002A (ja) | 2020-11-05 |
| JP2020531002A5 true JP2020531002A5 (enExample) | 2021-09-30 |
Family
ID=65361820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507675A Pending JP2020531002A (ja) | 2017-08-15 | 2018-08-15 | 獣医学用ｉｇｇ ｆｃ変異体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12297272B2 (enExample) |
| EP (1) | EP3668536A4 (enExample) |
| JP (1) | JP2020531002A (enExample) |
| KR (1) | KR20200057701A (enExample) |
| CN (2) | CN111182915A (enExample) |
| AU (3) | AU2018318440A1 (enExample) |
| BR (1) | BR112020002871A2 (enExample) |
| CA (1) | CA3071337A1 (enExample) |
| MX (1) | MX2020001707A (enExample) |
| WO (1) | WO2019035010A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019011860A2 (pt) | 2016-12-09 | 2019-11-12 | Akston Biosciences Corp | proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune |
| JP2020531002A (ja) | 2017-08-15 | 2020-11-05 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学用ｉｇｇ ｆｃ変異体 |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| EP4186920B1 (en) | 2018-06-29 | 2024-01-03 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| CN113194984A (zh) * | 2018-10-18 | 2021-07-30 | 金德雷德生物科学股份有限公司 | 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体 |
| MX2021007680A (es) * | 2018-12-27 | 2021-10-13 | Kindred Biosciences Inc | Variantes de igg fc para uso veterinario. |
| MA54657A (fr) | 2019-01-03 | 2021-11-10 | Invetx Inc | Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation |
| CN113840831A (zh) * | 2019-03-20 | 2021-12-24 | 金德雷德生物科学股份有限公司 | 医用ngf拮抗剂 |
| CA3143785A1 (en) | 2019-07-30 | 2021-02-04 | Hangjun Zhan | Parvovirus antibodies for veterinary use |
| DK4073098T5 (da) | 2019-12-19 | 2024-07-22 | Akston Biosciences Corp | Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| CA3167437A1 (en) | 2020-02-19 | 2021-08-26 | Verena BRAND | Modified fc regions |
| MX2022011335A (es) * | 2020-03-18 | 2022-10-07 | Kindred Biosciences Inc | Anticuerpos del receptor anti-interleucina 4 para uso veterinario. |
| HRP20230990T1 (hr) | 2020-04-10 | 2023-12-08 | Akston Biosciences Corporation | Antigen specifična imunoterapija za fuzijske proteine covid-19 i postupci uporabe |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| GB202005879D0 (en) * | 2020-04-22 | 2020-06-03 | Petmedix Ltd | Heterodimeric proteins |
| CA3173864A1 (en) * | 2020-04-22 | 2021-10-28 | Shyr Jiann Li | Long-acting anti-il31 antibodies for veterinary use |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| CA3178123A1 (en) | 2020-05-11 | 2021-11-18 | William Brondyk | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| WO2022010652A1 (en) | 2020-07-10 | 2022-01-13 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
| EP4199942A4 (en) * | 2020-08-24 | 2025-03-19 | The Trustees of The University of Pennsylvania | Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines |
| CN112625093B (zh) * | 2020-12-29 | 2022-12-23 | 清远市图微安创科技开发有限公司 | 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物 |
| EP4373861A4 (en) | 2021-07-23 | 2025-08-20 | Akston Biosciences Corp | INSULIN-FC FUSION PROTEINS AND METHODS OF USE FOR TREATING CANCER |
| WO2023012486A1 (en) * | 2021-08-06 | 2023-02-09 | Petmedix Ltd | Antibody fc variants |
| KR20250130357A (ko) | 2022-12-27 | 2025-09-01 | 인베티엑스 인코포레이티드 | 신생아 fc 수용체 (fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법 |
| KR20250151402A (ko) | 2023-01-20 | 2025-10-21 | 인베티엑스 인코포레이티드 | 반려 동물에서 사용하기 위한 이중특이적 결합제 |
| GB202311984D0 (en) * | 2023-08-04 | 2023-09-20 | Petmedix Ltd | Optimised fc molecules |
| WO2025166165A1 (en) * | 2024-02-01 | 2025-08-07 | Zoetis Services, Llc | Compositions and methods for modifying antibody effector functions |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6207383B1 (en) * | 1998-07-27 | 2001-03-27 | University Of Utah Research Foundation | Mutations in and genomic structure of HERG—a long QT syndrome gene |
| US7297482B2 (en) * | 1998-10-08 | 2007-11-20 | Rigel Pharmaceuticals, Inc. | Structurally biased random peptide libraries based on different scaffolds |
| EP1240196B1 (en) * | 1999-12-23 | 2010-09-08 | Universite De Geneve | Basolateral sorting signal based on scf peptide and inhibitors thereof |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| WO2002060919A2 (en) | 2000-12-12 | 2002-08-08 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| JP2004321100A (ja) | 2003-04-25 | 2004-11-18 | Rikogaku Shinkokai | ＩｇＧのＦｃ領域を含むタンパク質の変異体 |
| KR100758755B1 (ko) | 2003-06-12 | 2007-09-14 | 일라이 릴리 앤드 캄파니 | Ｇｌｐ-1 유사체 융합 단백질 |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| ES2326906T3 (es) | 2004-12-22 | 2009-10-21 | Eli Lilly And Company | Formulaciones de proteinas de fusion analogas al glp-1. |
| US20100104564A1 (en) * | 2005-03-29 | 2010-04-29 | Genevieve Hansen | Altered Antibody Fc Regions and Uses Thereof |
| US8658174B2 (en) * | 2005-07-27 | 2014-02-25 | Qinghua Wang | GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| EP2158318A2 (en) * | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| US20100196405A1 (en) | 2007-07-10 | 2010-08-05 | Kingman Ng | GLP-1 Fc FUSION PROTEIN FORMULATION |
| US20120009182A1 (en) * | 2008-12-23 | 2012-01-12 | Genentech, Inc. | Immunoglobulin variants with altered binding to protein a |
| US20120093814A1 (en) | 2009-03-30 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Fusion Proteins Comprising Canine FC Portions |
| WO2010117448A2 (en) | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| EP3208281A1 (en) | 2010-03-29 | 2017-08-23 | Zymeworks, Inc. | Antibodies with enhanced or suppressed effector function |
| AU2011288412A1 (en) | 2010-08-13 | 2013-02-21 | Medimmune Limited | Monomeric polypeptides comprising variant Fc regions and methods of use |
| AU2012234335B2 (en) | 2011-03-29 | 2016-09-01 | Roche Glycart Ag | Antibody Fc variants |
| SG10201500957QA (en) * | 2011-05-06 | 2015-04-29 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| CA2835094C (en) | 2011-05-06 | 2020-12-22 | David Gearing | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| EP2537864B1 (en) | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
| WO2013010840A2 (en) | 2011-07-18 | 2013-01-24 | Arts Biologics A/S | Long acting biologically active luteinizing hormone (lh) compound |
| AU2012285475B2 (en) | 2011-07-19 | 2017-09-14 | The National Institute For Biotechnology In The Negev, Ltd. | Novel IL-17R-ECD mutants |
| CA2853637C (en) | 2011-10-26 | 2023-04-04 | Novartis Ag | Anti-canine cd20 monoclonal antibodies and methods of use |
| EP2773671B1 (en) | 2011-11-04 | 2021-09-15 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| KR102041412B1 (ko) | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| AU2013223801B2 (en) * | 2012-02-22 | 2016-02-25 | Zoetis Services Llc | Tumour necrosis factor receptor fusion proteins and methods of using the same |
| US10011660B2 (en) | 2012-04-30 | 2018-07-03 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| EP2859018B1 (en) | 2012-06-06 | 2021-09-22 | Zoetis Services LLC | Caninized anti-ngf antibodies and methods thereof |
| JP2015524821A (ja) | 2012-08-02 | 2015-08-27 | ジェイエヌ バイオサイエンシーズ エルエルシー | システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質 |
| WO2014093387A1 (en) | 2012-12-10 | 2014-06-19 | Kindred Biosciences, Inc. | Vegf receptor fusion proteins for veterinary use |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| SG11201600734YA (en) | 2013-07-31 | 2016-02-26 | Amgen Inc | Stabilization of fc-containing polypeptides |
| WO2015022420A1 (en) | 2013-08-16 | 2015-02-19 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| WO2015091914A2 (en) | 2013-12-20 | 2015-06-25 | Intervet International B.V. | Caninized murine antibodies to human pd-1 |
| CN106456745A (zh) | 2014-02-11 | 2017-02-22 | 北京艾棣维欣生物技术有限公司 | 具有白细胞介素‑17作为佐剂的疫苗 |
| EP3194440A1 (en) | 2014-09-15 | 2017-07-26 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists |
| WO2016050721A1 (en) | 2014-09-30 | 2016-04-07 | Intervet International B.V. | Pd-l1 antibodies binding canine pd-l1 |
| MX2017005150A (es) | 2014-11-06 | 2017-08-08 | Hoffmann La Roche | Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a. |
| KR101825048B1 (ko) | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
| KR20170129902A (ko) | 2015-03-23 | 2017-11-27 | 조운스 테라퓨틱스, 인크. | Icos에 대한 항체 |
| EP3365011A1 (en) | 2015-10-19 | 2018-08-29 | Novartis AG | Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists |
| EP4541807A3 (en) | 2015-12-18 | 2025-09-24 | Intervet International B.V. | Caninized human antibodies to human and canine il-4r alpha |
| US20190111107A1 (en) | 2016-01-26 | 2019-04-18 | Defensin Therapeutics Aps | Methods for modulating intestinal microbiota |
| EP3416984B1 (en) | 2016-02-18 | 2021-03-31 | Elanco US Inc. | Chimeric canine anti-cd20 antibody |
| CN117535350A (zh) | 2016-05-20 | 2024-02-09 | 哈佛学院董事及会员团体 | 年龄相关疾病和病症的基因治疗方法 |
| CN110267674A (zh) | 2016-07-08 | 2019-09-20 | 奥美药业有限公司 | 包含瘦素的融合蛋白及其生产和使用方法 |
| EP3526246A1 (en) | 2016-10-17 | 2019-08-21 | Vetoquinol SA | Modified antibody constant region |
| EP3548073A4 (en) | 2016-12-02 | 2020-07-22 | The Texas A&M University System | FUSION PROTEINS FOR THE SELECTIVE DEPREVIRANT OF ANTIBODIES SPECIFIC TO AN ANTIGEN |
| WO2018195388A1 (en) * | 2017-04-21 | 2018-10-25 | Kindred Biosciences, Inc. | Il4/il13 receptor molecule for veterinary use |
| US11299540B2 (en) | 2017-06-18 | 2022-04-12 | Kindred Biosciences, Inc. | IL17A antibodies and antagonists for veterinary use |
| JP2020531002A (ja) | 2017-08-15 | 2020-11-05 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学用ｉｇｇ ｆｃ変異体 |
| EP4186920B1 (en) | 2018-06-29 | 2024-01-03 | Akston Biosciences Corporation | Ultra-long acting insulin-fc fusion proteins and methods of use |
| JP2022500037A (ja) | 2018-09-14 | 2022-01-04 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学的使用のための抗ｉｌ４受容体抗体 |
| CN113194984A (zh) | 2018-10-18 | 2021-07-30 | 金德雷德生物科学股份有限公司 | 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体 |
| WO2020086886A1 (en) | 2018-10-25 | 2020-04-30 | Kindred Biosciences, Inc. | Il4/il13 receptor molecule for veterinary use |
| CN113227134A (zh) | 2018-12-05 | 2021-08-06 | 株式会社梅花治疗 | 抗体的Fc区变体 |
| EP3894434A4 (en) | 2018-12-12 | 2022-09-07 | Kindred Biosciences, Inc. | ERYTHROPOIETIN ANALOGS FOR VETERINARY USE |
| MX2021007680A (es) | 2018-12-27 | 2021-10-13 | Kindred Biosciences Inc | Variantes de igg fc para uso veterinario. |
| MA54657A (fr) | 2019-01-03 | 2021-11-10 | Invetx Inc | Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation |
| CN113840831A (zh) | 2019-03-20 | 2021-12-24 | 金德雷德生物科学股份有限公司 | 医用ngf拮抗剂 |
| JP7762645B2 (ja) | 2019-08-22 | 2025-10-30 | シダラ セラピューティクス インコーポレーテッド | バリアントｆｃドメイン及びその使用 |
| WO2021043127A1 (zh) | 2019-09-02 | 2021-03-11 | 甘李药业股份有限公司 | 嵌合蛋白 |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| WO2021212084A1 (en) | 2020-04-17 | 2021-10-21 | Zoetis Services Llc | Feline antibody variants |
| CN115996949A (zh) | 2020-04-17 | 2023-04-21 | 硕腾服务有限责任公司 | 犬抗体变异体 |
| CA3173864A1 (en) | 2020-04-22 | 2021-10-28 | Shyr Jiann Li | Long-acting anti-il31 antibodies for veterinary use |
| JP2023522676A (ja) | 2020-04-22 | 2023-05-31 | キンドレッド バイオサイエンシズ インコーポレイテッド | 動物用のｉｌ４／ｉｌ１３受容体分子 |
| CA3178123A1 (en) | 2020-05-11 | 2021-11-18 | William Brondyk | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| CN115702169A (zh) | 2020-06-10 | 2023-02-14 | 株式会社梅花治疗 | 包含促红细胞生成素多肽的融合蛋白 |
| US20230250155A1 (en) | 2020-06-29 | 2023-08-10 | Zoetis Services Llc | Feline antibody variants for improving stability |
| WO2022010652A1 (en) | 2020-07-10 | 2022-01-13 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
| WO2022046941A1 (en) | 2020-08-26 | 2022-03-03 | Angiex, Inc. | Antimitotic tetrapeptide-antibody conjugates and methods of using same |
-
2018
- 2018-08-15 JP JP2020507675A patent/JP2020531002A/ja active Pending
- 2018-08-15 MX MX2020001707A patent/MX2020001707A/es unknown
- 2018-08-15 CN CN201880064650.9A patent/CN111182915A/zh active Pending
- 2018-08-15 CA CA3071337A patent/CA3071337A1/en active Pending
- 2018-08-15 BR BR112020002871-1A patent/BR112020002871A2/pt unknown
- 2018-08-15 KR KR1020207005513A patent/KR20200057701A/ko active Pending
- 2018-08-15 CN CN202411340586.6A patent/CN119390821A/zh active Pending
- 2018-08-15 AU AU2018318440A patent/AU2018318440A1/en not_active Abandoned
- 2018-08-15 WO PCT/IB2018/056142 patent/WO2019035010A1/en not_active Ceased
- 2018-08-15 EP EP18846242.8A patent/EP3668536A4/en active Pending
- 2018-08-15 US US16/638,402 patent/US12297272B2/en active Active
-
2023
- 2023-09-06 AU AU2023226676A patent/AU2023226676B2/en active Active
-
2025
- 2025-08-22 AU AU2025220819A patent/AU2025220819A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531002A5 (enExample) | ||
| JP7748393B2 (ja) | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 | |
| US20210122805A1 (en) | Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS | |
| CN113038964B (zh) | 超长效胰岛素-fc融合蛋白及使用方法 | |
| US12351622B2 (en) | Modified product of Fc domain of antibody | |
| JP7231553B2 (ja) | Ｔｇｆ－ｂ－受容体外部ドメイン融合分子及びその使用 | |
| JP5199876B2 (ja) | 一価ＩｇＧを生成するための方法 | |
| US10287336B2 (en) | Feline erythropoietin receptor agonists | |
| JP2017527272A5 (enExample) | ||
| US20130121959A1 (en) | Il-22-fc and hepcidin activity | |
| EP4166574A1 (en) | Fusion protein containing erythropoietin polypeptide | |
| CN117999289A (zh) | 具有延长的半衰期的抗体和IgG融合蛋白 |